Influence of various aministration routes on the antitumor efficacy of TT-232, a novel somatostatin analog

M. Tejeda, D. Gaál, R. E. Schwab, A. Pap, T. Szúts, G. Kéri

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

TT-232 a novel tumor-selective somatostatin analog with a five residue ring structure (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) was developed by us and published in an earlier work. This synthetic heptapeptide had no effect on growth hormone release, but had a remarkable tyrosine-kinase inhibitory effect and inducted apoptosis. The aim of this study was to term administration routes and treatment schedules. The effectiveness of TT-232 was studied on different rodent tumors transplanted to inbred mice from SPF breeding. Intermittent treatment by injections and continuous infusion of TT-232 using a s.c., i.p. or i.v. implanted Alzet type osmotic minipump were compared for therapeutic efficacy. The treatments were started either on the day subsequent to tumor transplantation or after the development of a tumor. On the basis of survival and tumor growth inhibition the infusion of TT-232 for 14 days using an implantable osmotic pump proved to be a much more effective route of treatment in both s.c. and i.v. administration than the intermittent injections applied twice a day for 2 weeks. In the case of S-180 sarcoma the continuous administration of TT-232 for 14 days using s.c. implanted osmotic pump resulted in 60% the i.v. infusion produced 40% long-term (over 80 days) and tumor free survivors. By the continuous administration of TT-232, an 80-100% tumor growth inhibitory effect and a considerable retardation of tumor development could be achieved. Continuous infusion from implanted pumps ensured a constant drug level and resulted in a well-defined, consistent pattern of drug exposure over the full duration of drug administration. In our study the route of infusion has been shown to increase drug efficacy relative to conventional delivery methods.

Original languageEnglish
Pages (from-to)1023-1027
Number of pages5
JournalAnticancer Research
Volume20
Issue number2 A
Publication statusPublished - 2000

Fingerprint

Somatostatin
Neoplasms
Pharmaceutical Preparations
Sarcoma 180
Therapeutics
Infusion Pumps
Injections
TT2-32
Growth
Protein-Tyrosine Kinases
Growth Hormone
Breeding
Rodentia
Appointments and Schedules
Transplantation
Apoptosis

Keywords

  • Alzet osmotic minipump
  • Continuous drug delivery
  • New somatostatin analog
  • TT-232
  • Tumor therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Influence of various aministration routes on the antitumor efficacy of TT-232, a novel somatostatin analog. / Tejeda, M.; Gaál, D.; Schwab, R. E.; Pap, A.; Szúts, T.; Kéri, G.

In: Anticancer Research, Vol. 20, No. 2 A, 2000, p. 1023-1027.

Research output: Contribution to journalArticle

@article{a8b21e3c978e4b988fceb7bbc26fd54e,
title = "Influence of various aministration routes on the antitumor efficacy of TT-232, a novel somatostatin analog",
abstract = "TT-232 a novel tumor-selective somatostatin analog with a five residue ring structure (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) was developed by us and published in an earlier work. This synthetic heptapeptide had no effect on growth hormone release, but had a remarkable tyrosine-kinase inhibitory effect and inducted apoptosis. The aim of this study was to term administration routes and treatment schedules. The effectiveness of TT-232 was studied on different rodent tumors transplanted to inbred mice from SPF breeding. Intermittent treatment by injections and continuous infusion of TT-232 using a s.c., i.p. or i.v. implanted Alzet type osmotic minipump were compared for therapeutic efficacy. The treatments were started either on the day subsequent to tumor transplantation or after the development of a tumor. On the basis of survival and tumor growth inhibition the infusion of TT-232 for 14 days using an implantable osmotic pump proved to be a much more effective route of treatment in both s.c. and i.v. administration than the intermittent injections applied twice a day for 2 weeks. In the case of S-180 sarcoma the continuous administration of TT-232 for 14 days using s.c. implanted osmotic pump resulted in 60{\%} the i.v. infusion produced 40{\%} long-term (over 80 days) and tumor free survivors. By the continuous administration of TT-232, an 80-100{\%} tumor growth inhibitory effect and a considerable retardation of tumor development could be achieved. Continuous infusion from implanted pumps ensured a constant drug level and resulted in a well-defined, consistent pattern of drug exposure over the full duration of drug administration. In our study the route of infusion has been shown to increase drug efficacy relative to conventional delivery methods.",
keywords = "Alzet osmotic minipump, Continuous drug delivery, New somatostatin analog, TT-232, Tumor therapy",
author = "M. Tejeda and D. Ga{\'a}l and Schwab, {R. E.} and A. Pap and T. Sz{\'u}ts and G. K{\'e}ri",
year = "2000",
language = "English",
volume = "20",
pages = "1023--1027",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Influence of various aministration routes on the antitumor efficacy of TT-232, a novel somatostatin analog

AU - Tejeda, M.

AU - Gaál, D.

AU - Schwab, R. E.

AU - Pap, A.

AU - Szúts, T.

AU - Kéri, G.

PY - 2000

Y1 - 2000

N2 - TT-232 a novel tumor-selective somatostatin analog with a five residue ring structure (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) was developed by us and published in an earlier work. This synthetic heptapeptide had no effect on growth hormone release, but had a remarkable tyrosine-kinase inhibitory effect and inducted apoptosis. The aim of this study was to term administration routes and treatment schedules. The effectiveness of TT-232 was studied on different rodent tumors transplanted to inbred mice from SPF breeding. Intermittent treatment by injections and continuous infusion of TT-232 using a s.c., i.p. or i.v. implanted Alzet type osmotic minipump were compared for therapeutic efficacy. The treatments were started either on the day subsequent to tumor transplantation or after the development of a tumor. On the basis of survival and tumor growth inhibition the infusion of TT-232 for 14 days using an implantable osmotic pump proved to be a much more effective route of treatment in both s.c. and i.v. administration than the intermittent injections applied twice a day for 2 weeks. In the case of S-180 sarcoma the continuous administration of TT-232 for 14 days using s.c. implanted osmotic pump resulted in 60% the i.v. infusion produced 40% long-term (over 80 days) and tumor free survivors. By the continuous administration of TT-232, an 80-100% tumor growth inhibitory effect and a considerable retardation of tumor development could be achieved. Continuous infusion from implanted pumps ensured a constant drug level and resulted in a well-defined, consistent pattern of drug exposure over the full duration of drug administration. In our study the route of infusion has been shown to increase drug efficacy relative to conventional delivery methods.

AB - TT-232 a novel tumor-selective somatostatin analog with a five residue ring structure (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) was developed by us and published in an earlier work. This synthetic heptapeptide had no effect on growth hormone release, but had a remarkable tyrosine-kinase inhibitory effect and inducted apoptosis. The aim of this study was to term administration routes and treatment schedules. The effectiveness of TT-232 was studied on different rodent tumors transplanted to inbred mice from SPF breeding. Intermittent treatment by injections and continuous infusion of TT-232 using a s.c., i.p. or i.v. implanted Alzet type osmotic minipump were compared for therapeutic efficacy. The treatments were started either on the day subsequent to tumor transplantation or after the development of a tumor. On the basis of survival and tumor growth inhibition the infusion of TT-232 for 14 days using an implantable osmotic pump proved to be a much more effective route of treatment in both s.c. and i.v. administration than the intermittent injections applied twice a day for 2 weeks. In the case of S-180 sarcoma the continuous administration of TT-232 for 14 days using s.c. implanted osmotic pump resulted in 60% the i.v. infusion produced 40% long-term (over 80 days) and tumor free survivors. By the continuous administration of TT-232, an 80-100% tumor growth inhibitory effect and a considerable retardation of tumor development could be achieved. Continuous infusion from implanted pumps ensured a constant drug level and resulted in a well-defined, consistent pattern of drug exposure over the full duration of drug administration. In our study the route of infusion has been shown to increase drug efficacy relative to conventional delivery methods.

KW - Alzet osmotic minipump

KW - Continuous drug delivery

KW - New somatostatin analog

KW - TT-232

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=0033625685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033625685&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 1023

EP - 1027

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -